Congenital cytomegalovirus infection
Intrauterine infection with cytomegalovirus (CMV), a betaherpesvirus, remains the most frequent congenital virus infection in many regions of the world. Although most CMV-infected newborns lack signs of CMV infection, approximately 10% have signs that can consist of low birth weight, jaundice, hepatosplenomegaly, skin rash, microcephaly, and chorioretinitis. Neonates with signs of CMV infection at birth have high rates of audiologic and neurodevelopmental sequelae. Although postnatal therapy with ganciclovir transiently reduces virus shedding and may lessen the audiologic consequences of CMV in some infected infants, additional strategies are needed to prevent congenital CMV disease and to improve the neurodevelopmental prognosis of infants infected with CMV in utero. Some cases of intrauterine infections can be prevented in susceptible women by avoiding contact with the urine or saliva of young children who may be shedding CMV. Vaccines against CMV remain in the experimental stages of development. Termination of pregnancy can be offered to women whose infants have evidence of intrauterine CMV infection and sonographic signs of central nervous system damage. Infants who survive symptomatic intrauterine infections have high rates of neurodevelopmental sequelae and require comprehensive evaluation and therapy through center and home-based early intervention programs.
KeywordsGanciclovir Sensorineural Hearing Loss Intrauterine Infection Ganciclovir Therapy Congenital Cytomegalovirus Infection
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Bale JF Jr., Jordan MC: Cytomegalovirus. In Handbook of Clinical Neurology, vol 12: Viral Disease. Edited by Vinken PJ, Bruyn GW, Klawans HL. Amsterdam: Elsevier Publications; 1989:263–279.Google Scholar
- 3.Britt WJ, Alford CA: Cytomegalovirus. In Fields Virology, edn 3. Edited by Fields BN, Knipe DM, Howley JM. Philadelphia: Lippincott-Raven; 1996:2493–2523.Google Scholar
- 11.Boppana SB, Rivera LB, Fowler KB, et al.: Intrauterine transmission of cytomegalovirus to infants of mothers with preconceptional immunity. N Engl J Med 2001, 344:1366–1371. This important observation indicates that some mothers can become reinfected with new CMV strains and deliver congenitally infected infants despite the presence of pre-existing antibodies against CMV.PubMedCrossRefGoogle Scholar
- 14.Noyola DE, Demmler GJ, Nelson CT, et al.: Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr 2001, 138:325–331. This longitudinal study describes the outcome of infants with symptomatic, intrauterine CMV infections and the relationship of clinical and radiographic features to outcome. An abnormality detected by CT was a sensitive predictor of mental retardation and motor disability.PubMedCrossRefGoogle Scholar
- 22.Kimberlin DW, Lin CY, Sanchez P, et al.: Ganciclovir (GCV) treatment of symptomatic congenital cytomegalovirus (CMV) infection: results of a phase III randomized trial. Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, ON.September 17–20, 2000; This abstract describes the long-awaited results of a randomized trial of ganciclovir therapy in infants with congenital CMV disease. Like the phase II study, this study suggested that ganciclovir therapy provides some protection from hearing deterioration in infants with congenital CMV infections. Neutropenia was a major side effect of therapy.Google Scholar